ProPhase Labs

DOYLESTOWN, PA - April 18, 2005 - The Quigley Corporation (Nasdaq: QGLY), announced today that its Quigley Pharma Division had completed a double-blind placebo controlled study of its QR-340 Scar Formula. Initial results demonstrated that the formula was safe, effective and outperformed Mederma®, the top selling scar appearance formula in the commercial marketplace.

The main objectives of the study were to evaluate the cosmetic effect of QR-340 on surgical scar appearance when applied to an area of suture removal and to evaluate the safety of the study products, as compared to placebo and Mederma®.

The QR340 formula is a blend of botanical derived ingredients delivered in an easily applied topical hydrophilic ointment. The study participants were enrolled and monitored for 12 weeks by a well-known surgical clinic in Philadelphia and received QR-340, placebo or Mederma®. The study design focused on the clinicians and patients assessment of five recognized post surgery cosmetic evaluations: reduction in scar area, mean scar width change, scar area change, scar percent change in area and mean scar scale evaluation.

The results of the study showed that QR-340 helps reduce overall scar area post surgery better than placebo or Mederma® in every assessment as measured by the 5 cosmetic evaluations. QR-340 was six times more effective then the placebo, twice as effective as Mederma® for improving scar width and area appearance, showed positive results earlier than placebo or Mederma®, and was shown to be safe and well tolerated by the participants.

"Over 50 Million Americans form scars from burns, injuries and surgeries each year and an increasing interest in finding ways to enhance physical appearance has led to a growing demand for products that can minimize the appearance of scars. We are excited about entering this estimated $60 million market by developing this compound into a cosmetic product and look forward to discussing commercialization with potential strategic partners," said Guy Quigley, president, The Quigley Corporation.

The Company has a patent pending for QR-340 with the Patent Office of the U.S Department of Commerce.

Quigley Pharma has a number of other formulations currently in its pipeline.

Mederma® is a registered trademark of Merz Pharmaceuticals.

About Quigley Pharma

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading developer and marketer of diversified health products including the COLD-EEZE® family of patented zinc gluconate glycine (ZIGG™) lozenges and sugar free tablets. In September of 2004, The Company has also formed a wholly owned subsidiary, Quigley Manufacturing, Inc. with the acquisition of two FDA approved facilities to manufacture its COLD- EEZE® branded lozenges. InnerLight, Inc., a wholly owned subsidiary, was formed in January 2001 for the purpose of introducing new products to the marketplace through a network of independent distributors. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of naturally derived patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND or take any other action to allow the aforementioned products to be studied or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.